In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C

Hepato-Gastroenterology

Volumn 53, Issue 71, 2006, Pages 693-697

  Le Page, Sébastien ^a   Kwiatkowski, Fabrice ^c   Paulin, Christian ^b   Mohamed F, Faheez ^d   Pezet, Denis ^e   Chipponi, Jacques ^e   Benhamed, Mohamed ^b   Gilly, François Noël ^a,f   Glehen, Olivier ^a,f  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE JEAN PERRIN   (France)

^d WASHINGTON CANCER INSTITUTE   (United States)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Colorectal cancer; CPT 11; Hyperthermia; Thermosensivity; Tumor cell line

Indexed keywords

IRINOTECAN; MITOMYCIN C;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN CACO 2; COLON CANCER; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIA; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 33750590092     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dancey J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74:327-338.
2. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
4. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-4191.
5. Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J: Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002; 49:329-335.
6. Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH: Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 2001; 76:106-114.
7. Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA, Jr., et al: Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 1988; 11:368-380.
8. Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980; 40:1165-1168.
9. Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al: Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000; 88:2512-2519.
10. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92:71-76.
11. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, et al: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003; 21:799-806.
12. Bacher A, Griebl K, Mackamul S, Mitreiter R, Muckter H, Ben-Shaul Y: Protease inhibitors suppress the formation of tight junctions in gastrointestinal cell lines. Exp Cell Res 1992; 200:97-104.
13. Fogh J: Human tumor cells in vitro. New York: Plenum Press, 1975.
14. Caignard A, Martin MS, Michel MF, Martin F: Interaction between two cellular subpopulations of a rat colonic carcinoma when inoculated to the syngeneic host. Int J Cancer 1985; 36:273-279.
15. Kwiatkowski M, Girard M, Hacène K, Berlie J: SEM software: a suitable software for research in cancerology. Bull Cancer 2000; 87:715-721.
16. Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W, Larsson R: Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer 2000; 36:2120-2127.
17. Murakami A, Koga S, Maeta M: Thermochemosensitivity: augmentation by hyperthermia of cytotoxicity of anticancer drugs against human colorectal cancers, measured by the human tumor clonogenic assay. Oncology 1988; 45:236-241.
18. Meyn RE, Corry PM, Fletcher SE, Demetriades M: Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 1980; 40:1136-1139.
19. Kondo T, Ueda K, Kano E: Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells. Anticancer Res 1995; 15:83-86.
20. Herman TS: Effect of temperature on the cytotoxicity of vindesine, amsacrine, and mitoxantrone. Cancer Treat Rep 1983; 67:1019-1022.
21. Rofstad EK, Midthjell H, Brustad T: Heat sensitivity and thermotolerance in cells from five human melanoma xenografts. Cancer Res 1984; 44:4347-4354.
22. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P: Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998; 42:165-170.
23. Maruyama M, Nagahama T, Yuasa Y: Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis. Anticancer Res 1999; 19:4187-4191.
24. Machida Y, Onishi H, Kurita A, Hata H, Morikawa A: Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J Control Release 2000; 66:159-175.
25. Maruyama M, Toukairin Y, Baba H, Kure N, Nagahama T, Ebuchi M: [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers]. Gan To Kagaku Ryoho 2001; 28:1505-1507.
26. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al: Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138:26-33.
27. Hribaschek A, Pross M, Kuhn R, Kruger S, Ridwelski K, Halangk W, et al: Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin. Anticancer Drugs 2002; 13:605-614.
28. Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, et al: Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123:6-12.
29. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13:267-272.